Clinical trial · Interventional
Plant Exosomes and Patients Diagnosed With Polycystic Ovary Syndrome (PCOS) 17
A Preliminary Clinical Trial Investigating the Ability of Plant Exosomes to Mitigate Insulin Resistance and Chronic Inflammation in Patients Diagnosed With Polycystic Ovary Syndrome (PCOS)
NCT03493984CI-TRIAL-00050685withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Investigator left the university prior to study approval, no patients enrolled
Summary
Brief summary (as posted)
The purpose of this study is to see if substances contained in ginger or aloe plants, called exosomes, will treat and improve the condition polycystic ovary syndrome
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aloe exosomes | Other | — | UNRESOLVED |
| Ginger exosomes | Other | — | UNRESOLVED |
| Placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Ginger exosomes
- interventionNames
- Other: Ginger exosomes
- type
- EXPERIMENTAL
- label
- Aloe exosomes
- interventionNames
- Other: Aloe exosomes
- type
- EXPERIMENTAL
- label
- Ginger and aloe exosomes
- interventionNames
- Other: Ginger exosomes
- Other: Aloe exosomes
- type
- PLACEBO_COMPARATOR
- label
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18-40 year * Patients must have a confirmed diagnosis of PCOS according to the Rotterdam Criteria. At least 2 of the following 3 characteristics must be present: 1. Oligo-anovulation 2. Clinical and/or biochemical signs of androgen excess and 3. Polycystic ovarian morphology (PCOM) (defined by an increased number of small antral follicles \[≥12 follicles that were \<10 mm in diameter\] or an increased individual ovarian volume \[\>10 cm3\] in 1 or both ovaries. Disorders mimicking PCOS must also be excluded, including thyroid dysfunction, hyperprolactinemia, late-onset congenital adrenal hyperplasia, and ovarian or adrenal androgen-producing tumors. * Of all subjects screened patients must be informed of the investigational nature of this study and give written informed consent in accordance with institutional and federal guidelines. * Ability to understand and willingness to sign a written informed consent document. * Absence of life limiting medical conditions Exclusion Criteria: * • Pregnancy * Known HIV * Patients receiving immunosuppressive drugs * Patients taking confounding medications such as sex steroids, infertility medications or insulin sensitizers or any medication deemed to alter glucose and/or insulin levels * Active malignancy in the last 5 years * Patients receiving any other investigational agent(s) * Ginger and/or aloe allergy
References
Publications (0)
Data not yet available
No reference posted for this study.